Articles tagged "Antibodies"

2019 American Transplant Congress
Use of mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Breaking False Myths
D. Cucchiari¹, A. Molina-Andujar¹, E. Montagud-Marrahi¹, F. J. Centellas-Pérez², I. Revuelta¹, F. Oppenheimer¹, F. Diekmann¹
¹Renal Transplant Unit, Hospital Clínic, Barcelona, Spain, ²Complejo Hospitalario Universitario, Albacete, Spain
*Purpose: Many centers avoid the use of mTOR inhibitors (mTORi) in hypersensitized kidney transplant recipients and usually employ an immunosuppression based on Mycophenolic Acid (MPA),…
2019 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
M. Raijmakers¹, A. Shetty², R. Hod Dvorai², A. Tambur², M. G. Ison²
¹University of Santiago, Santiago, Chile, ²Northwestern University Comprehensive Transplant Center, Chicago, IL
*Purpose: To determine the development of de novodonor specific antibodies (DSA) in renal transplant recipients with immunosuppression modulation and BK viremia and the associated risk…
2019 American Transplant Congress
Variable Glycosylations of Anti-HLA Antibodies Detected with Single Antigen Beads in Kidney Transplant Recipients
Y. Chang¹, N. Lemp², J. Cicciarelli¹, T. Shah³, D. Min⁴
¹Mendez National Institute of Transplantation Foundation, Los Angeles, CA, ²Transplantation Research, Mendez National Institute of Transplantation Foundation, Los Angeles, CA, ³St. Vincent Medical Center, Los Angeles, CA, ⁴Western Univ of Health Sciences, Pomona, CA
*Purpose: Differential glycosylation of Immunoglobulin G (IgG) is known to affect its effector functions by modulating interactions with its binding partners, such as C1q or…
2018 American Transplant Congress
The Role of Donor-Derived Cell-Free DNA in Identification of Injury in Kidney Allografts with Antibody-Mediated Rejection and De Novo DSA
H. Zhang,¹ L. Liu,¹ C. Zheng,² X. Li,¹ Q. Fu,¹ J. Li,¹ Q. Su,¹ H. Huang,¹ M. Ye,² C. Wang.¹
¹Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; ²BGI-Guangzhou Medical Laboratory, BGI-Shenzhen, Guangzhou, China.
Objectives: To evaluate the capacity of donor-derived cell-free DNA (dd-cfDNA) in the identification of injury in kidney allografts with antibody-mediated rejection and de novo DSA.Methods:…
2018 American Transplant Congress
Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss
R. Sapir-Pichhadze,¹ X. Zhang,¹ A. Ferradji,¹ A. Madbouly,² S. Fingerson,² K. Tinckam,⁵ H. Gebel,³ H. Cardinal,⁴ B. Foster.¹
¹McGill University, Montreal, Canada; ²National Marrow Donor Program, Minneapolis; ³Emory University Hospital, Atlanta; ⁴CHUM, Montreal, Canada; ⁵University Health Network, Toronto, Canada.
Introduction: HLA matching at the epitope level offers new opportunities to identify compatible donors for transplant candidates. HLAMatchmaker deduces B-cell epitope ('eplets' in HLAMatchmaker) mismatches…
2018 American Transplant Congress
Protocolar Biopsies in Patients with Subclinical De Novo DSA in Kidney Transplantation
D. Bertrand,¹ M. Jaureguy,² C. Garrouste,³ J. Sayegh,⁴ N. Bouvier,⁵ S. Caillard,⁶ L. Lanfranco,⁷ A. Galinier,⁸ A. François,⁹ F. Hau,¹⁰ I. Etienne,¹ P. Gatault.¹¹
¹Nephrology Kidney Transplantation Dialysis, CHU Rouen, Rouen, France; ²Nephrology Kidney Transplantation, CHU Amiens, Amiens, France; ³Nephrology Kidney Transplantation, CHU Clermont Ferrand, Clermont Ferrand, France; ⁴Nephrology Kidney Transplantation, CHU Angers, Angers, France; ⁵Nephrology Kidney Transplantation, CHU Caen, Caen, France; ⁶Nephrology Kidney Transplantation, CHU Strasbourg, Strasbourg, France; ⁷Nephrology Kidney Transplantation, CHU Brest, Brest, France; ⁸Nephrology Kidney Transplantation, CHU Poitiers, Poitiers, France; ⁹Pathology, CHU Rouen, Rouen, France; ¹⁰EFS Normandie, EFS Normandie, Rouen, France; ¹¹Nephrology Kidney Transplantation, CHU Tours, Tours, France.
De novo donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and allograft loss. The aim of our study was to examine the histology associated…
2018 American Transplant Congress
Peripheral but Not Follicular T Helper Cells Are Activated by Allogeneic Human Endothelial Cells under IRI-Like Conditions and Promote Donor Specific Antibody
W. Fu,¹ P. Yoo,² J. Pober,³ D. Jane-wit.¹
¹Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; ²Surgery, Yale School of Medicine, New Haven, CT; ³Immunobiology, Yale School of Medicine, New Haven, CT.
Background: Perioperative ischemia reperfusion injury (IRI) is a consequence of solid organ allograft transplantation that primes the graft for future rejection.Methods: We developed an in…
2018 American Transplant Congress
The Impact of Duration on Dialysis on the Pre-Transplant Allosensitization According to Panel Reactive Antibody Levels
Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,² J. Lee,³ B. Kim,⁴ J. Lee,¹ S. Kim,¹ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, College of Medicine, Ewha Women's University, Seoul, Republic of Korea; ³Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; ⁴Departments of Nephrology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Purpose : Presensitization to human leukocyte antigen(HLA) is one of the most important barriers to overcome in the field of renal transplantation. Due to the…
2018 American Transplant Congress
Feasibility of a National Class II Matching Strategy for Pediatric Kidney Transplant Candidates
T. Blydt-Hansen,¹ W. Klement,² K. Tinckam,³ J. Gill.¹
¹University of British Columbia, Vancouver, Canada; ²Canadian Blood Services, Ottawa, Canada; ³University of Toronto, Toronto, Canada.
Antibody-mediated rejection (AMR) is a major concern for allograft failure, which could be mitigated by allocation of Class II matched donors. Since children have priority,…
2018 American Transplant Congress
Treatment of Active Chronic Antibody-Mediated Rejection with Rituximab, IVIG and Plasma Exchange
G. Piñeiro,¹ J. Rovira,² E. De Sousa-Amorim,¹ J. Villarreal,¹ M. Sole,³ I. Revuelta,¹ M. Lozano,⁴ E. Palou,⁴ F. Oppenheimer,¹ J. Campistol,¹ F. Diekmann.^1,2
¹Nephrology and Renal Transplantation, Hospital Clinic de Barcelona, Barcelona, Spain; ²Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ³Pathology, Hospital Clinic de Barcelona, Barcelona, Spain; ⁴Apheresis Unit, Hemotherapy and Hemostasis, Hospital Clinic de Barcelona, Barcelona, Spain; ⁵Immunology, Hospital Clinic de Barcelona, Barcelona, Spain.
Chronic antibody-mediated rejection (cABMR) and transplant glomerulopathy (TG) are main features associated with long-term graft loss. Despite its clinical significance, the available evidence on treatment…